Related Experiment Video
Updated: Sep 3, 2025
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.0K
Avapritinib for advanced systemic mastocytosis
Jason Gotlib1, Andreas Reiter2, Daniel J DeAngelo3
1Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Blood
|July 25, 2022
Summary
Avapritinib effectively treats advanced systemic mastocytosis by targeting the KIT D816V mutation, leading to durable responses and molecular remission. This targeted therapy addresses a key challenge in managing this complex blood cancer.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Advanced systemic mastocytosis (AdvSM) presents complex mutational landscapes, often with associated hematologic neoplasms.
- KIT D816V mutation is a key driver in many AdvSM cases.
- Effective targeted therapies are crucial for managing AdvSM.
Purpose of the Study:
- To evaluate the efficacy and safety of avapritinib in patients with advanced systemic mastocytosis.
- To assess the ability of avapritinib to achieve clinical response and molecular remission.
- To understand the role of avapritinib in managing complex AdvSM cases.
Main Methods:
- Phase 1 EXPLORER and Phase 2 PATHFINDER clinical trials.
- Avapritinib, a selective KIT D816V inhibitor, was administered to patients with AdvSM.
- Clinical response, molecular remission, and safety were assessed.
Main Results:
- Avapritinib demonstrated complete and durable clinical responses in patients with AdvSM.
- Molecular remission of the KIT D816V mutation was achieved.
- The drug showed a manageable safety profile in the studied populations.
Conclusions:
- Avapritinib is an effective targeted therapy for advanced systemic mastocytosis, particularly those with KIT D816V mutation.
- The drug offers durable clinical and molecular benefits, addressing a significant unmet need.
- Avapritinib represents a valuable treatment option for AdvSM, including cases with complex mutational profiles.
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
256
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
256
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
248
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
248
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
250
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
250